Officials at x-ray manufacturer Del Global Technologies believe the company has added an important European dimension to its Valhalla, NY-based business by increasing its ownership in Villa Sistemi Medicali, an Italian radiographic/fluoroscopic firm.In
Officials at x-ray manufacturer Del Global Technologies believe the company has added an important European dimension to its Valhalla, NY-based business by increasing its ownership in Villa Sistemi Medicali, an Italian radiographic/fluoroscopic firm.
In January, Del Global obtained a 19% stake in Villa along with the nonrevocable option to increase its share to 80%.
In April, Del Global decided to exercise its option.
Villa Sistemi has annual sales of $20 million. Its line of radiographic/fluoroscopic systems and a line of portable imaging systems with power ratings up to 30 kW complements Del Globals existing line of products, said Leonard Trugman, Del Globals president.
Getting into the European imaging market has been one of Del Globals goals over the last five years, Trugman said. Before the Villa Sistemi acquisition, medical salessystems and subsystemsaccounted for 80% of Del Globals total sales (SCAN 2/2/00). The acquisition drives that to 90%.
Prior to 1990, Del Global manufactured mostly defense electronics.
The company shifted toward medical imaging in the early 1990s, primarily by acquiring companies that specialized in niche technologies Del Global lacked (SCAN 2/2/00).
Del Global purchased x-ray and mammography firm DynaRad in 1992, and in 1996 bought Gendex Medical from Dentsply International. In 1998, Del Global acquired Acoma Medical Imaging for $1.4 million. That year, the company posted the strongest fourth-quarter and fiscal-year results in its history. Year-end sales for 1998 were $62.3 million (SCAN 11/11/98).
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.